spacer
home > epc > winter 2003 > ippc drives the emissions control agenda
PUBLICATIONS
European Pharmaceutical Contractor

IPPC Drives the Emissions Control Agenda

A new legislative framework designed to protect the environment and minimise waste and pollution - the integrated pollution, prevention and control (IPPC) regulations - is currently being implemented across EU member states, bringing with it a surge of interest in emissions abatement technologies among industries where harmful emissions are produced or used. Many pharmaceutical industry manufacturers are significant solvent-users, employing a wide range of organic solvents as part of everyday production processes. These solvents, or volatile organic compounds (VOCs), are harmful air pollutants and can be released at various stages of the production process from reactor vents, storage tanks and vacuum pumps. The current legislative focus on curbing air pollution means that managers of solvent-using industries are seeking ways of eliminating emissions from onsite processes. Some are waiting for developments in 'green chemistry', in the hope that solvent replacements can be found, while others are investing in long- term technological solutions that are both efficient and flexible. But as time runs out for IPPC compliance, how long can such industries afford to wait and what are the technological options open to them?

Tried and Tested Technologies

For more than a decade, many different forms of abatement technology have been tried and tested by pharmaceutical and chemical industry manufacturers. Their aim has been to recover harmful VOC emissions at their industrial source. Carbon activated technologies have been widely used, which work by trapping the VOC molecules in the pores of the carbon surface before removing them from the gas stream. Liquid carriers are also used and work by absorbing the solvent, which is dissolved and later recovered through a process of distillation.

However, the fastest developing area of technological development in emissions control, and the one which holds most promise in terms of achieving zero emissions targets, is cryogenic technology. This technology works by using liquid nitrogen to condense and effectively freeze out the VOCs from process gas streams. The benefits of VOC recovery are obvious. Not only does effective recovery protect the environment and ensure legislative compliance, but many VOCs also have a relatively high market value and can be reused. By far the main driver in the take up of solvent abatement technology, however, is legislation and keeping up with the pace of legislative change has become a primary managerial issue.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Diana Raine, Business Manager for Cryogenics in Europe at Air Products

Diana Raine is Air Products' Business Manager for Cryogenics in Europe and specialises in finding applications for cryogenic technology in modern industrial processes. She joined the company 12 years ago with a Masters degree in Chemical Engineering.

spacer
Diana Raine
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement